中国临床药理学杂志2017，Vol.33Issue(3)：213-215,3.DOI:10.13699/j.cnki.1001-6821.2017.03.006
米氮平片联合帕罗西汀片治疗女性重度抑郁症的临床研究
Clinical trial of mirtazapine tablets combined with paroxetine tablets in the treatment of women with severe depression
摘要
Abstract
Objective To observe the clinical efficacy and safety of mirtazapine tablets combined with paroxetine tablets in the treatment of women with severe depression.Methods A total of 58 women with severe depression were randomly divided into control group and treatment group with 29 cases per group.Control group orally received the initial dose of paroxetine 20 mg qd,the maximum dose was 50 mg qd with adjusting for tolerability.Treatment group was orally given the initial dose of mirtazapine 15 mg qd,the maximum dose was 30 mg qd,on the basis of the control group.Two groups were treated for 6 weeks.The clinical efficacy,5-hydroxytryptamine (5-HT),dobaamine,norepinephrine and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 82.76％ (24/29 cases) and 58.62％ (17/29 cases) with significant difference (P ＜ 0.05).After treatment,the main indexes in treatment and control groups were compared:5-HT were (150.28 ± 19.49),(124.29 ± 15.59)pg · mL-1;dobaamine were (215.29 ± 25.29),(248.39 ± 29.29) μg · L-1;norepinephrine were (230.92 ± 25.69),(255.39 ± 26.77) pg · mL-1,the differences were statistically significant (P ＜ 0.05).The adverse drug reactions in treatment group were loss of appetite,dizziness,constipation,fatigue and sweating,which in control group were sedative drowsiness,loss of appetite,dry mouth and elevated alanine aminotransferase.The incidences of adverse drug reactions in treatment and control groups were 20.69％ and 24.14％ without significant difference (P ＞ 0.05).Conclusion Mirtazapine tablets combined with paroxetine tablets have a definitive clinical efficacy in the treatment of women with severe depression,without increasing the incidence of adverse drug reactions.关键词
米氮平/帕罗西汀/女性重度抑郁症/安全性Key words
mirtazapine/paroxetine/women with severe depression/safety分类
医药卫生引用本文复制引用
徐兵,陈梅,李智,何效兵..米氮平片联合帕罗西汀片治疗女性重度抑郁症的临床研究[J].中国临床药理学杂志,2017,33(3):213-215,3.基金项目
国家自然科学基金(青年科学基金)资助项目(81001427) （青年科学基金）
